AZN · story · 28 October
AstraZeneca · 5 headlines from 5 outlets, on 28 October 2026.
CEO Pascal Soriot says AstraZeneca could move into cancer vaccine development building on mRNA groundwork.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Investing.com is the largest at 4.2, ahead of Briefs Finance (4.2). Quartz is the smallest at 3.7.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Investing.com | 4.2 |
| Briefs Finance | 4.2 |
| Bloomberg | 3.8 |
| Quartz | 3.7 |
| Seeking Alpha | 3.7 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Investing.com | 1 | +4.2 |
| Briefs Finance | 1 | +4.2 |
| Bloomberg | 1 | +3.8 |
| Quartz | 1 | +3.7 |
| Seeking Alpha | 1 | +3.7 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +4.2 | CEO open to vaccine development; potential new growth area. |
| +4.2 | Possible expansion into cancer vaccines building on mRNA work. |
| +3.8 | Potential move into vaccine research per chief executive. |
| +3.7 | CEO floats entering vaccines; exploratory only. |
| +3.7 | Considering vaccine development, early and uncommitted. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.